The same bacteria was further found in 51 out of 53 brain autopsies of Alzheimer's disease patients, according to new research by Dr. Stephen Dominy and Casey Lynch, founders of the pharmaceutical firm Cortexyme.
The team also tested blocking the bacteria in mice by injecting small molecules targeting Pg, to inhibit it and found that it could reduce neurodegeneration in the brain, showing a potential new way to tackle Alzheimer's disease.
Lynch further added that it also shows a "promising approach" to address the disease.
Lynch further added that while previous studies have established a link between periodontal disease and Alzheimer's, the new research observes a "highly significant" link between Alzheimer's and the oral infection and that the mouse study indicates causation.
Alzheimer's disease is the most common form of dementia, characterised by memory loss that increases over time. It is believed to be caused by a buildup of beta amyloid plaques and neurofibrillary tangles called tau in the brain. There is no cure for the disease as of yet.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)